Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMR) under the UK Disclosure Guidance and Transparency Rules (DTR 3.1.4R(1)(a)).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding executive compensation awards rather than a financial results report.
Material Changes
The filing discloses a change in the share interests of N Hirons, a Person Discharging Managerial Responsibility. On September 24, 2014, Hirons received awards under the GlaxoSmithKline Deferred Investment Award programme. These awards relate to employment prior to his appointment to the Corporate Executive Committee.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies. It details the terms of the Deferred Investment Award programme, noting that awards are made over notional Ordinary Shares, do not accrue dividends, and are paid in cash upon vesting. Vesting is conditional on the individual not having served notice or been terminated for cause.
Important Facts for Investors
- Award Recipient: N Hirons (PDMR).
- Award Details: Two tranches of notional Ordinary Shares totaling 32,429 shares (17,489 vesting August 26, 2016; 14,940 vesting February 12, 2017).
- Share Price: The closing middle market price on September 24, 2014, was £14.285.
- Eligibility: Executive Directors are explicitly ineligible for this specific programme.
- Payout Structure: Awards are cash-settled upon vesting and do not include dividend accruals.